Selinexor, Pomalidomide, and Dexamethasone For Multiple Myeloma With CNS Involvement
Status:
Recruiting
Trial end date:
2024-07-10
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label, multicenter, exploratory study initiated by investigator to
evaluate the efficacy and safety of Selinexor (S) combined with pomalidomide (P) and
dexamethasone (D) in the treatment of multiple myeloma with CNS involvement.